ES104: Potential First-in-Class Anti-VEGFxDLL4 Bispecific Antibody in China
ES104 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. VEGF also plays an important role in creating an immune suppressive TME.
Pre-clinical and early clinical data of ES104 show that blocking both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses to ES104 as a monotherapy have been observed in heavily pre-treated cancer patients, who were resistant to currently approved anti-VEGF therapies. Positive interim ES104 Phase 2 data in combination with paclitaxel in patients with biliary tract cancers (BTC) was also reported in May 2022.
In China, Elpiscience licensed ES104 greater China rights from Compass Therapeutics in January 2021 and is currently under Phase 1/2 study (NCT05167448) for the treatment of unresectable locally advanced or metastatic colorectal cancer (CRC). ES104 is currently the only clinical-stage bispecific antibody targeting VEGF and DLL4 in China.
Mechanism of Action
ES104 has showed robust anti-tumor activity in preclinical study, and partial responses to ES104 as a monotherapy have been observed in heavily pre-treated cancer patients, who were resistant to currently approved anti-VEGF therapies. AACR 2021